Levofloxacin-Doxycycline for Helicobacter Pylori Eradication in Saudi Arabia

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Helicobacter pylori (H. pylori) eradication is achieved in 60-80% with first-line therapy. Different second-line therapeutic options are available. However, the success of second-line therapy has not been addressed or reported from Saudi Arabia.

Objectives The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King Faisal Specialist Hospital & Research Center
• Treatments: Doxycycline; Esomeprazole; Levofloxacin; Ofloxacin

Criteria

Inclusion Criteria:

• 18 years of age or older

• Received previous treatment with triple therapy, sequential therapy or both

• Has evidence of persistence H. pylori infection by a positive urea breath test (UBT), histology or rapid urease test (HP Fast. GI supply™, PA, USA)

Exclusion Criteria:

• Previously treated with quadruple or levofloxacin-based therapy

• Had an allergy to doxycycline, levofloxacin or esomeprazole

• Pregnant or lactating

• Significant hepatic, renal, or cardiopulmonary disorders, or active malignancy.